[Treatment of acquired inhibitors of coagulation factors].
Takatoshi
T
Koyama
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000933:Antifibrinolytic Agents / Q000008:administration & dosage; D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005165:Factor V / Q000276:immunology; D005169:Factor VIII / Q000276:immunology*; D015942:Factor VIIa / Q000008:administration & dosage*; D005176:Factor XIII / Q000276:immunology; D006467:Hemophilia A / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006487:Hemostasis; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D011239:Prednisolone / Q000008:administration & dosage*; D011516:Prothrombin / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage; D000069283:Rituximab; D014148:Tranexamic Acid / Q000008:administration & dosage
D058846:Antibodies, Monoclonal, Murine-Derived; D000933:Antifibrinolytic Agents; D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D000069283:Rituximab; D014148:Tranexamic Acid; D003520:Cyclophosphamide; D005165:Factor V; D011516:Prothrombin; D005169:Factor VIII; D005176:Factor XIII; D011239:Prednisolone; D015942:Factor VIIa